ESR1 and breast carcinoma: Abemaciclib also demonstrates single-agent activity and is approved for use in both monotherapy and combination regimens.95 Its mechanism involves Rb-mediated G1 arrest, resulting in anti-proliferative effects in estrogen receptor-positive (ER+) breast cancer cells.